Our research focuses on the proteogenomic understanding of cancer biology and treatment innovation. The past two decades have witnessed the progression of personalized tumor therapy driven by advanced genomic studies (e.g. the TCGA). However, the understanding of tumor systems biology at protein level remains a knowledge gap. Since postdoc, I have been among the leading data analytic team of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), which uses mass spectrometry (MS)-based proteomics to profile the global protein expression and post-translational modifications (PTMs) for multiple cancer types. Integrating these proteomic data to genomic knowledge, we have brought the proteogenomic research to an unprecedented level for protein marker and drug target discovery. Currently in the lab, we strive to improve the computational approaches for tumor proteogenomic data analysis and the clinical translation of proteogenomic findings. Specifically, our projects will drive the functional interpretation of genomic aberration, signaling pathway understanding by protein and PTM dynamics, and immunotherapeutic target discovery and drug repurposing, all of which will see the advancement of integration between genomics and proteomics.
